MBX Biosciences, Inc.
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -22.41% | -93.56% | -76.25% | -78.51% | -108.43% |
| Total Depreciation and Amortization | -3.17% | 60.42% | 41.46% | 87.50% | 61.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 97.62% | -54.15% | -76.95% | 4.46% | 487.21% |
| Change in Net Operating Assets | -54.53% | 38.25% | 78.05% | 54.63% | 1,879.41% |
| Cash from Operations | -31.38% | -111.75% | -43.88% | -89.80% | -79.79% |
| Capital Expenditure | -56.42% | 89.01% | -67.27% | -159.09% | -1,358.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 458.83% | -79.26% | -132.71% | -442.06% | -137.20% |
| Cash from Investing | 429.31% | -79.09% | -132.59% | -441.73% | -139.52% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,552.00% | -97.88% | 926.32% | 1,026,435.29% | -92.11% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -7.31% | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -7,223.33% | -- |
| Cash from Financing | 175.30% | -97.81% | -794.74% | 244.27% | -377.76% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 143.09% | -496.74% | -108.36% | 185.45% | -273.36% |